Literature DB >> 28870584

Relevance of CCM gene polymorphisms for clinical management of sporadic cerebral cavernous malformations.

Carmela Rinaldi1, Placido Bramanti2, Concetta Scimone3, Luigi Donato3, Concetta Alafaci1, Rosalia D'Angelo4, Antonina Sidoti3.   

Abstract

Cerebral cavernous malformations (CCMs) are clusters of capillaries in the brain that may cause focal deficits or seizures in affected patients. They occur in both sporadic and inherited autosomal dominant form. Germline mutations in CCM1, CCM2 and CCM3 were identified in familial cases. Over the past 13years we performed sequencing and MLPA of the CCM genes in all sporadic and familial CCM cases coming from some hospital clinics of Neurology and Neurosurgery of Messina and other Italian cities. Our results showed that CCM sporadic patients, negative for previously reported CCM gene causative mutations, always carried known CCM polymorphisms. Previously, we reported polymorphisms in CCM2 gene associated with an increase in risk for CCM. Here, we undertook a case-control study to investigate the possible association of others polymorphisms (c.485+65 C/G, c.989+63 C/G, c.1980 A/G in CCM1 gene, c.472+127 C/T in CCM2 and c.150 G/A in CCM3) with CCMs. The five polymorphisms were characterized in 64 sporadic patients and in 90 healthy controls by ASO-PCR. Statistically significant differences in frequencies between patients and controls were found for c.485+65C/G, c.1980 A/G and c.472+127C/T polymorphisms. For c.485+65C/G polymorphism, a higher frequency of mutated allele (G) was found in patients group (9%) than in controls (2%) (p=0.0041); for c.1980 A/G polymorphism, we found a frequency of mutated allele (G) higher in the control group (25%) compared to that of patients (8%) (p=0.0396). Same trend was observed for c.472+127C/T polymorphism (T allele frequency=34% and 6% in control group and patients, respectively; p=0.0001). Polymorphisms c.485+65C/G, c.1980 A/G and c.472+127C/T were associated with an increased risk of CCM as indicated by odds ratio values. Furthermore, c.1980 A/G and c.472+127C/T polymorphisms were associated with less severe CCM symptomatology. Identification of these polymorphisms in CCM sporadic patient may represent a useful tool for clinicians to determine prognosis, scheduled periodic checks and appropriate treatment strategy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebral cavernous malformations; Clinical management; Haplotype analysis; Polymorphisms

Mesh:

Substances:

Year:  2017        PMID: 28870584     DOI: 10.1016/j.jns.2017.06.043

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Vis-à-vis: a focus on genetic features of cerebral cavernous malformations and brain arteriovenous malformations pathogenesis.

Authors:  Concetta Scimone; Luigi Donato; Silvia Marino; Concetta Alafaci; Rosalia D'Angelo; Antonina Sidoti
Journal:  Neurol Sci       Date:  2018-12-06       Impact factor: 3.307

Review 2.  Genetics of brain arteriovenous malformations and cerebral cavernous malformations.

Authors:  Hiroki Hongo; Satoru Miyawaki; Yu Teranishi; Daiichiro Ishigami; Kenta Ohara; Yu Sakai; Daisuke Shimada; Motoyuki Umekawa; Satoshi Koizumi; Hideaki Ono; Hirofumi Nakatomi; Nobuhito Saito
Journal:  J Hum Genet       Date:  2022-07-13       Impact factor: 3.755

3.  HOXC-AS2 mediates the proliferation, apoptosis, and migration of non-small cell lung cancer by combining with HOXC13 gene.

Authors:  Bin Liu; Jing Li; Ji-Man Li; Guang-Yuan Liu; Yong-Sheng Wang
Journal:  Cell Cycle       Date:  2021-01-11       Impact factor: 4.534

4.  Up-regulating microRNA-138-5p enhances the protective role of dexmedetomidine on myocardial ischemia-reperfusion injury mice via down-regulating Ltb4r1.

Authors:  Yanzi Chang; Lika Xing; Wenjuan Zhou; Wei Zhang
Journal:  Cell Cycle       Date:  2021-01-28       Impact factor: 4.534

5.  RNAi-mediated knockdown of PFK1 decreases the invasive capability and metastasis of nasopharyngeal carcinoma cell line, CNE-2.

Authors:  Shuo Li; Peng He; Zhiwei Wang; Meng Liang; Wei Liao; Yili Huang; Mengshi Chi; Fei Liu; Nan Zen; Rongfei Su; Shulin Chen; Zhigang Liu; Haiyu Hong
Journal:  Cell Cycle       Date:  2021-01-06       Impact factor: 4.534

6.  Crocin inhibits the activation of mouse hepatic stellate cells via the lnc-LFAR1/MTF-1/GDNF pathway.

Authors:  Ji Xuan; Dongmei Zhu; Zhengyuan Cheng; Yuping Qiu; Mei Shao; Ya Yang; Qi Zhai; Fangyu Wang; Feng Qin
Journal:  Cell Cycle       Date:  2020-12-09       Impact factor: 4.534

7.  The circ_0004463/miR-380-3p/FOXO1 axis modulates mitochondrial respiration and bladder cancer cell apoptosis.

Authors:  Shuiqing Wu; Huanghao Deng; Haiqing He; Ran Xu; Yinhuai Wang; Xuan Zhu; Jinhua Zhang; Qi Zeng; Xiaokun Zhao
Journal:  Cell Cycle       Date:  2020-12-07       Impact factor: 4.534

8.  Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model.

Authors:  Yuki Matsumi; Tetsuya Kagawa; Shuya Yano; Hiroshi Tazawa; Kunitoshi Shigeyasu; Sho Takeda; Toshiaki Ohara; Hiromichi Aono; Robert M Hoffman; Toshiyoshi Fujiwara; Hiroyuki Kishimoto
Journal:  Cell Cycle       Date:  2021-06-10       Impact factor: 5.173

Review 9.  SMADS-Mediate Molecular Mechanisms in Sjögren's Syndrome.

Authors:  Margherita Sisto; Domenico Ribatti; Sabrina Lisi
Journal:  Int J Mol Sci       Date:  2021-03-21       Impact factor: 5.923

Review 10.  It takes two to tango: coupling of Hippo pathway and redox signaling in biological process.

Authors:  Jianan Zheng; Hui Yu; Anqi Zhou; Bingfeng Wu; Jiayi Liu; Yinan Jia; Lin Xiang
Journal:  Cell Cycle       Date:  2020-10-04       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.